Stevia First Corp. operates as an agricultural biotechnology company in the United States. The company engages primarily in developing methods and technologies for industrial production of stevia, along with discovery and development of additional food and nutritional products. The company is developing and commercializing healthier food and nutrition products. Stevia is a zero-calorie alternative sweetener that is enabling sugar reduction within mainstream food and beverage products. The company is developing proprietary stevia processing technologies to increase its global supply, and intend to sell stevia at an industrial scale directly to multinational food, beverage, and ingredient companies. The company is also developing and using a bioinformatics platform that relies on artificial intelligence algorithms discover novel genes and gene combinations related to longevity, which can be used to develop medical interventions for common age-associated diseases. The company focuses on selling products through business-to-business arrangements or partnerships with multinational companies, although it would also seek to market certain products directly to consumers including stevia and other functional food and nutraceuticals that may be useful for prevention of diabetes and weight management. In 2014, the company initiated a research products business, which it owns and operates, and that provides a sales channel for certain research products and tools that it has developed, as well as new commercialization opportunities related to new technologies and trends that are of strategic interest to the company. The company’s commercial operations include its pursuit of sales of stevia extract to multinational food and beverage companies focused mainly on North America. The company’s sales and distribution operations provide North American stevia sales, marketing, and quality control support, and also provides a distribution channel for any food and nutrition products made internally using its bioprocessing methods. The company’s commercial operations also include a research products business, which entails commercialization of life sciences research products and tools, some of which are also used within its own research and development activities. Strategy The company’s strategy of differentiation in the nutraceutical and functional ingredient market is to provide a high level of quality and consistency in its products, a clear ability for its products to influence metabolic health, and to validate its products using clinical study practices that are comparable to those used by the pharmaceutical industry. Intellectual Property The company has obtained or applied for exclusive and worldwide rights to multiple patents and patent families, most of which have been developed internally, but also, including rights obtained through an exclusive license agreement with Vineland Research and Innovations Centre (the Vineland License). The Vineland License relates to certain methods for microbial production of steviol and steviol glycosides that are derived from a U.S. patent application titled, Compositions and methods for producing steviol and steviol glycosides. The Vineland License has an initial term of 10 years and may be renewed by the company for additional two-year terms until all licensed patents have expired, which is March 19, 2027 for U.S. Patent No. 7927851, March 20, 2027 for European Union Patent No. EP1897951B1, and March 21, 2027 for Canadian Patent No. 2580429. The company’s internally developed patents include provisional and non-provisional patent applications filed in the United States in 2013, 2014, and 2015 covering biosynthesis methods for steviol glycosides, enzyme enhancement methods, use of agricultural drones and robotic systems in agriculture, and methods for combined processing of sugar and stevia leaf extract. Research and Development During the fiscal year ended March 31, 2015, the company incurred $1,131,327 in expenses that were allocated to research and development activities. Competition The company’s major competitors for its stevia business are existing stevia producers in Japan, Korea, China and Malaysia. These competitors include Cargill, Incorporated; GLG Life Tech Corp.; Evolva Holding SA; Blue California Inc.; Corn Products International, Inc.; DSM Nutritional Products; and PureCircle Limited. Government Regulation In addition to laws and regulations enforced by the U.S. Food and Drug Administration and those related to the sale of stevia leaf or refined stevia extract as a food, beverage or ingredient, the company is also subject to regulations under the Occupational Safety and Health Act, other labor and employment laws, and other present and potential future federal, state or local laws and regulations applicable to its operations as an agricultural biotechnology company. Further, the company’s agricultural operations are subject to a range of evolving environmental laws and regulations. These laws and regulations include the Clean Air Act, the Clean Water Act, the Resource Conservation and Recovery Act, the Federal Insecticide, Fungicide and Rodenticide Act and the Comprehensive Environmental Response, Compensation and Liability Act. History The company was founded in 2007. It was incorporated under the laws of the state of Nevada in 2007. The company was formerly known as Legend Mining Inc. and changed its name to Stevia First Corp. in 2011.
stevia first corp (STVF:OTC US)
5225 Carlson Road
Yuba City, CA 95993
|Evolva Holding SA||SFr.1.26 CHF||0.00|
|GLG Life Tech Corp||C$0.34 CAD||+0.01|
|Ingredion Inc||$90.61 USD||+0.37|
|PureCircle Ltd||409.50 GBp||-5.50|
|Takeda Pharmaceutical Co Ltd||¥5,505 JPY||+82.00|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact STEVIA FIRST CORP, please visit www.steviafirst.com. Company data is provided by Capital IQ. Please use this form to report any data issues.